Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis

被引:122
作者
Hutchinson, Carol
Geissler, Catherine A.
Powell, Jonathan J.
Bomford, Adrian
机构
[1] Kings Coll Hosp London, Inst Liver Studies, Iron Metab Interdisciplinary Res Grp, London SE5 9RS, England
[2] MRC Human Nutr Res, Cambridge, England
基金
英国医学研究理事会;
关键词
D O I
10.1136/gut.2006.108613
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: During the long-term treatment of patients with hereditary haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) reduced the requirement for maintenance phlebotomy. Gastric acid plays a crucial role in non-haem iron absorption and the authors performed a case review and intervention study to investigate if PPI-induced suppression of gastric acid would reduce dietary iron absorption in C282Y homozygous patients. Methods: Phlebotomy requirements to keep serum ferritin similar to 50 mu g/l before (mean 6.1 (SE 0.6) years) and during (3.8 (0.9) years) administration of a PPI were evaluated in seven patients and a post-prandial study was performed to determine whether PPIs reduce absorption of non-haem iron (14.5 mg) from a test meal in a further 14 phlebotomised patients with normal iron stores. Results: There was a significant reduction (p < 0.001) in the volume of blood removed annually before (2.5 (0.25) l) and while taking (0.5 (0.25) l) a PPI. Administration of a PPI for 7d suppressed absorption of non-haem iron from the meal as shown by a significant reduction (all p < 0.01) in: area under the serum curve (2145 (374) versus 1059 (219)), % recovery of administered iron at peak serum iron (20.5 (3.2) versus 11.0 (2.0)%) and peak serum iron (13.6 (2.4) vs 6.1 (1.2) mu mol/l) (all values are before vs during PPI). Conclusions: Administration of a PPI to patients with HH can inhibit the absorption of non-haem iron from a test meal and the habitual diet.
引用
收藏
页码:1291 / 1295
页数:5
相关论文
共 40 条
  • [1] ARCHAMBAULT AP, 1967, GASTROENTEROLOGY, V52, P940
  • [2] BEZWODA W, 1978, J LAB CLIN MED, V92, P108
  • [3] Genetics of haemochromatosis
    Bomford, A
    [J]. LANCET, 2002, 360 (9346) : 1673 - 1681
  • [4] BOMFORD A, 1976, Q J MED, V45, P611
  • [5] Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis
    Bridle, KR
    Frazer, DM
    Wilkins, SJ
    Dixon, JL
    Purdie, DM
    Crawford, DHG
    Subramaniam, VN
    Powell, LW
    Anderson, GJ
    Ramm, GA
    [J]. LANCET, 2003, 361 (9358) : 669 - 673
  • [6] Champagne E T, 1989, Adv Exp Med Biol, V249, P173
  • [7] Serum iron curves can be used to estimate dietary iron bioavailability in humans
    Conway, Rana E.
    Geissler, Catherine A.
    Hider, Robert C.
    Thompson, Richard P. H.
    Powell, Jonathan J.
    [J]. JOURNAL OF NUTRITION, 2006, 136 (07) : 1910 - 1914
  • [8] DAVIS WD, 1952, J LAB CLIN MED, V39, P526
  • [9] Dooley J., 2000, GUIDELINES DIAGNOSIS, P1
  • [10] Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron
    Gehrke, SG
    Kulaksiz, H
    Herrmann, T
    Riedel, HD
    Bents, K
    Veltkamp, C
    Stremmel, W
    [J]. BLOOD, 2003, 102 (01) : 371 - 376